Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 5, Mai 2008
Page(s) 470 - 472
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2008245470
Publié en ligne 15 mai 2008
  1. Wrogemann K, Pena SD. Mitochondrial calcium overload: a general mechanism for cell-necrosis in muscle diseases. Lancet 1976; 1 : 672–4.
  2. Millay DP, Sargent MA, Osinska H, et al. Genetic and pharmacologic inhibition of mitochondrialdependent necrosis attenuates muscular dystrophy. Nat Med 2008; 14 : 442–7.
  3. Merlini L, Angelin A, Tiepolo T, et al. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci USA 2008; 105 : 5225–9.
  4. Karpati G, Hilton-Jones D, Griggs R. Disorders of voluntary muscle, 7e ed. Cambridge : Cambridge University Press, 2001 : 776 p.
  5. Kaplan JC. The 2008 version of the gene table of neuromuscular disorders. Neuromuscul Disord 2008; 18 : 99–129. (http://194.167.35.195/).
  6. Allard B. Sarcolemmal ion channels in dystrophin-deficient skeletal muscle fibres. J Muscle Res Cell Motil 2006; 27 : 367–73.
  7. Constantin B, Sébille S, Cognard C. New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: implications in DMD. J Muscle Res Cell Motil 2006; 27 : 375–86.
  8. Ruegg UT, Nicolas-Metral V, Challet C, et al. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. Neuromuscul Disord 2002; 12 (suppl 1) : S155–61.
  9. Bernardi P, Colonna R, Costantini P, et al. The mitochondrial permeability transition. Biofactors 1998; 8 : 273–81.
  10. Bernardi P. Mitochondria in muscle cell death. Ital J Neurol Sci 1999; 20 : 395–400.
  11. Bernardi P, Krauskopf A, Basso E, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J 2006; 273 : 2077–99.
  12. Bernardi P, Rasola A. Calcium and cell death: the mitochondrial connection. Subcell Biochem 2007; 45 : 481–506.
  13. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341 : 233–49.
  14. Halestrap AP. The mitochondrial permeability transition: its molecular mechanism and role in reperfusion injury. Biochem Soc Symp 1999; 66 : 181–203.
  15. Halestrap A. Biochemistry: a pore way to die. Nature 2005; 434 : 578–9.
  16. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434 : 658–62.
  17. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434 : 652–8.
  18. Waldmeier PC, Zimmermann K, Qian T, et al. Cyclophilin D as a drug target. Curr Med Chem 2003; 10 : 1485–506.
  19. Hansson MJ, Mattiasson G, Mansson R, et al. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain derived mitochondria. J Bioenerg Biomembr 2004; 36 : 407–13.
  20. Bonaldo P, Braghetta P, Zanetti M, et al. Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet 1998; 7 : 2135–40.
  21. Irwin WA, Bergamin N, Sabatelli P, et al. Mitochondrialdysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet 2003; 35 : 367–71.
  22. Angelin A, Tiepolo T, Sabatelli P, et al. Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc Natl Acad Sci USA 2007; 104 : 991–6.
  23. Armstrong JS. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 2007; 151 : 1154–65.
  24. Miller RG, Sharma KR, Pavlath GK, et al. Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve 1997; 20 : 469–78.
  25. De Luca A, Nico B, Liantonio A, et al. A multidisciplinary evaluation of the effectiveness of cyclosporine A in dystrophic mdx mice. Am J Pathol 2005; 166 : 477–89.
  26. www.parentprojectmd.org/site/DocServer/interview_korinthenberg.pdf
  27. Stupka N, Gregorevic P, Plant DR, Lynch GS. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol 2004; 107 : 299–310.
  28. Stupka N, Schertzer JD, Bassel-Duby R, et al. Stimulation of calcineurin A (alpha) activity attenuates muscle pathophysiology in mdx dystrophic mice. Am J Physiol Regul Integr Comp Physiol 2008; 294 : R983–92.
  29. St-Pierre SJ, Chakkalakal JV, Kolodziejczyk SM, et al. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J 2004; 18 : 1937–9.
  30. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43 : 761–70.
  31. Ptak RG, Gallay PA, Jochmans D, et al. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother 2008; 52 : 1302–17.
  32. Teichgraber V, Ulrich M, Endlich N, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008; 14 : 382–91.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.